2000
Pharmacogenetics and the serotonin system: initial studies and future directions
Veenstra-VanderWeele J, Anderson G, Cook E. Pharmacogenetics and the serotonin system: initial studies and future directions. European Journal Of Pharmacology 2000, 410: 165-181. PMID: 11134668, DOI: 10.1016/s0014-2999(00)00814-1.Peer-Reviewed Original Research
1998
A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome
Peterson B, Zhang H, Anderson G, Leckman J. A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome. Journal Of Clinical Psychopharmacology 1998, 18: 324-331.. PMID: 9690699, DOI: 10.1097/00004714-199808000-00013.Peer-Reviewed Original ResearchConceptsAndrogen receptor blockadeReceptor blockadeCrossover trialHormone levelsSyndrome patientsSelective androgen receptor antagonistAdult TS subjectsTreatment of ticsTourette syndrome patientsTic symptom severitySerious side effectsAndrogen receptor antagonistSymptom severity ratingsTS prevalenceClinic visitsFlutamide administrationEndocrine findingsObsessive-compulsive disorderReceptor antagonistAndrogen receptorPhysiologic compensationTherapeutic effectPhysiologic mechanismsSide effectsTourette syndrome
1996
Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls
Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biological Psychiatry 1996, 39: 776-783. PMID: 8731518, DOI: 10.1016/0006-3223(95)00221-9.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing factorCSF corticotropin-releasing factorTourette syndromeObsessive-compulsive disorderNormal controlsCerebrospinal fluidPathobiology of TSOCD patientsMedication-free outpatientsCompulsive disorderLumbar cerebrospinal fluidNoradrenergic mechanismsHealthy controlsTS patientsObsessive-compulsive behaviorTic severityCardinal featuresClinical ratingsPatientsSyndromeRelated conditionsStandardized fashionNeurobiological mechanismsGroup differencesDisorders
1995
Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls. Neuropsychopharmacology 1995, 12: 73-86. PMID: 7766289, DOI: 10.1038/sj.npp.1380241.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndromeCerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995, 12: 73-86. DOI: 10.1016/0893-133x(94)00070-g.Peer-Reviewed Original ResearchObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndrome
1994
Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder: Comparison With Tourette's Syndrome and Healthy Controls
Leckman J, Goodman W, North W, Chappell P, Price L, Pauls D, Anderson G, Riddle M, McSwiggan-Hardin M, McDougle C, Barr L, Cohen D. Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder: Comparison With Tourette's Syndrome and Healthy Controls. JAMA Psychiatry 1994, 51: 782-792. PMID: 7524462, DOI: 10.1001/archpsyc.1994.03950100030003.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid levelsObsessive-compulsive disorderCSF oxytocin levelsTourette syndromeArginine vasopressinFamily historyFluid levelsElevated cerebrospinal fluid levelsTic-related obsessive-compulsive disorderOxytocin levelsSubgroup of patientsSubset of patientsElevated CSF levelsCentral arginine vasopressinSubtype of OCDCSF levelsFamily genetic dataHealthy controlsTic disordersForms of OCDPatientsRelated syndromesCurrent severitySyndromeFamily study dataThe role of central oxytocin in obsessive compulsive disorder and related normal behavior
Leckman J, Goodman W, North W, Chappell P, Price L, Pauls D, Anderson G, Riddle M, McDougle C, Barr L, Cohen D. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology 1994, 19: 723-749. PMID: 7991761, DOI: 10.1016/0306-4530(94)90021-3.Peer-Reviewed Original ResearchConceptsForms of OCDObsessive-compulsive disorderCompulsive disorderCentral oxytocinFeatures of OCDDimensions of behaviorSeries of predictionsBehavioral symptomsOxytocinChallenge proceduresNormal behaviorSexual behaviorAnecdotal dataDisordersExtreme endsBehaviorAlternative hypothesisTreatment responseRelationship
1992
Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder
RIDDLE M, SCAHILL L, KING R, HARDIN M, ANDERSON G, ORT S, SMITH J, LECKMAN J, COHEN D. Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 1992, 31: 1062-1069. PMID: 1429406, DOI: 10.1097/00004583-199211000-00011.Peer-Reviewed Original ResearchConceptsChildren's Yale-Brown Obsessive Compulsive ScaleObsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleEffective short-term treatmentSafety of fluoxetineFixed-dose trialCommon drug side effectsCY-BOCS total scoreMajor depressive disorderShort-term treatmentDrug side effectsMagnitude of improvementObsessive Compulsive ScaleFluoxetine groupPlacebo groupFluoxetine treatmentCrossover trialClinical trialsDepressive disorderObsessive-compulsive symptom severitySide effectsFluoxetineSymptom severityTotal scoreCompulsive Scale
1991
Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment
KING R, RIDDLE M, CHAPPELL P, HARDIN M, ANDERSON G, LOMBROSO P, SCAHILL L. Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment. Journal Of The American Academy Of Child & Adolescent Psychiatry 1991, 30: 179-186. PMID: 2016219, DOI: 10.1097/00004583-199103000-00003.Peer-Reviewed Original ResearchConceptsFluoxetine treatmentObsessive-compulsive disorderUniversity Clinical Research CenterClinical Research CenterMajor risk factorDrug-induced activationPrior suicidal ideationYounger patientsRisk factorsRegulation of aggressionPatientsSuicidal ideationSelf-destructive behaviorFluoxetineAge 10Apparent associationVulnerable individualsDisordersTreatmentIdeationDe novoHospitalizationSymptoms